ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy

First comprehensive spatial atlas of healthy human tissue from multiple organs, including multi-cell and single cell resolution using both GeoMx and CosMx

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced the launch of the Spatial Atlas of Human Anatomy (SAHA) initiative, in collaboration with Weill Cornell Medicine, to create multicellular, single-cell, and sub-cellular maps of 30 non-diseased organs from a healthy and diverse population of adults.

SAHA is a foundational effort to map 250 million cells at two spatial scales: whole transcriptome of histological features (50 µm to 2 mm in length) and 1,000 RNAs and 64 proteins at single cell resolution (50 nm resolution across 1 cm2). The project will establish best practices in experimental design, data analysis, and data standards for high-content spatial analysis across multiple human organs at a whole transcriptome and proteome level. The goal is to create a comprehensive open source, spatial reference standard that can be accessed by researchers around the globe to advance our knowledge of spatial biology.

“The goal is for SAHA to be a foundational database that can serve as a benchmark reference for spatial precision medicine. Comparing spatial datasets of various organs from multiple ethnicities can capture the variability in samples that researchers do not currently understand,” stated Chris Mason, Professor of Physiology and Biophysics, Weill Cornell Medicine. “The research team plans to show how spatial organ atlasing at multiple scales can be used for uncovering unique insights into organ development, health, and cancer.”

Dr. Mason will be presenting an overview of the SAHA study on Monday, February 6th at 6:10pm ET, at the Advances in Genome Biology and Technology conference in Hollywood, FL.

The GeoMx® Digital Spatial Profiler (DSP) will measure the expression of whole transcriptomes matched to the exact shape of functional and structural histological organ features. In addition, the 1,000-plex RNA profiles and 64-plex protein profiles collected by the CosMx™ Spatial Molecular Imager (SMI) will enable the highest-ever subcellular resolution single-cell maps of cell types, lineage states, metabolic capacity, cellular neighborhoods, subcellular movements of organelles, while also detailing spatially resolved and novel ligand-receptor interactions.

“The SAHA data set, obtained at multiple spatial scales, analyte classes, and plex-levels, represents the largest data set of its kind ever collected,” said Joseph Beechem, SVP & CSO of NanoString. “This atlas will transform our understanding of how healthy tissues are organized and function and provide the foundation of understanding required to both treat and diagnose disease states.”

Variability is an important aspect of biological research. The samples, selected to advance medical research, will capture variability across sexes and ancestries (European, African, Latin American, East Asian, and South Asian). All results will be made available to the scientific community through the SAHA data portal, including raw and processed data.

SAHA is a collaborative effort with Weill Cornell Medicine’s Department of Pathology and Laboratory Medicine, Englander Institute for Precision Medicine, and the WorldQuant Initiative for Quantitative Prediction. It will be led by Drs. Chris Mason, Robert E. Schwartz, and Shauna L. Houlihan, and executed in two phases over the next three years. The research will investigate how NanoString’s spatial platforms can synergize for unprecedented biological insights.

Dr. Mason serves on the Scientific Advisory Board and is a paid consultant to NanoString

About NanoString Technologies, Inc.

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler, cited in more than 190 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx™ Spatial Molecular Imager (SMI) is an FFPE-compatible, single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform (SIP) is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. The foundation of our research tools is our nCounter® Analysis System, cited in more than 6,500 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.

For more information, visit www.nanostring.com.

Contacts

Doug Farrell, NanoString

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.